Actively Recruiting
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
Led by University of Chicago · Updated on 2025-12-29
100
Participants Needed
5
Research Sites
331 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to ensure that the total radiation dose they receive is still effective and similar to the radiation dose they would receive if they were not participating in this study (standard treatment).
CONDITIONS
Official Title
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of primary cervical cancer or uterine cancer of any histology
- Age 18 years or older
- Non-metastatic disease according to International Federation of Gynecology and Obstetrics (FIGO)
- Treated with definitive intent including standard-of-care hysterectomy without gross residual disease post-operatively
- If no nodal dissection performed, diagnostic imaging confirming absence of gross pelvic or para-aortic disease pre- or post-operatively
- Recommended to undergo whole pelvic radiotherapy without concurrent chemotherapy or para-aortic radiation
- Chemotherapy before or after radiotherapy is acceptable
- Eastern Cooperative Oncology Group (ECOG) performance status 2 or less
- Able to provide informed consent and willing to sign consent form
You will not qualify if you...
- Presence of distant metastases based on clinical or radiographic evaluation
- Concurrent chemotherapy during the study
- Gross residual disease post-operatively or at radiation based on imaging or clinical judgment
- History of small bowel obstruction, inflammatory bowel disease, irritable bowel syndrome, connective tissue disorder requiring ongoing treatment, or prior pelvic radiation therapy
- Unresolved grade 2 or higher chemotherapy-associated diarrhea or abdominopelvic pain requiring medication before radiation
- Recommendation to receive para-aortic nodal irradiation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States, 30322
Active, Not Recruiting
2
University of Illinois at Chicago (UIC)
Chicago, Illinois, United States, 60612
Actively Recruiting
3
University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
4
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
5
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Actively Recruiting
Research Team
C
Christina Son, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here